Menu
Skip to content
For patients
Benefits
Area of application
Procedure & costs
MARK53 Knowledge
The biomarker
For all types of cancer
The Mark53 analysis
Quality assurance
Mark53 Studies
Colorectal cancer
Liver metastases
Oesophageal cancer
Biomarker studies
Press review
Press review 2016
Press review 2015
Press review 2014
Press review 2013
Press review 2002
MARK53-findings
MARK53-Board
MARK53 affiliated doctors
About us
Contact
Press kit
Request Mark53
Cancer therapy: more efficient – less side effects
Press review 2002
“Wenn ein Gen-Gendarm wehrlos ist”
–
mehr lesen
Die Presse, 15. Oktober 2002